Last checked at 4 Nov 2016 07:00
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Grant of Options
The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets near patient technologies to facilitate the development of treatments for neurological disorders, announces that on 3 November 2016, the Company granted options ("Options") over a total of 1,150,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's EMI option scheme and the Company's unapproved option scheme.
Of these Options:
- 550,000 were granted to Steven Powell, Chief Executive Officer of the Company;
- 150,000 were granted to Nick Walters, Chief Financial Officer of the Company;
- 175,000 were granted to other Persons Discharging Managerial Responsibilities ("PDMRs") on behalf of the Company; and
- 275,000 were granted to other employees of the Company.
Name | Position | Total number of new Options granted | Total number of Options now held | Percentage of the Company's current share capital now held under Option | Number of Ordinary Shares currently held | Percentage of the Company's current share capital held |
Steven Powell | Chief Executive Officer | 550,000 | 675,000 | 3.3% | 70,541 | 0.3% |
Nick Walters | Chief Financial Officer | 150,000 | 300,000 | 1.5% | 186,937 | 0.9% |
The Options are exercisable at a price of 1 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to satisfying the following performance criteria:
- 55% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for the final 10 trading days of 2018 is greater than 140 pence per Ordinary Share. A pro rata sliding scale will apply if the average closing mid-market price of an Ordinary Share for the final 10 trading days of 2018 is between 100 pence and 140 pence per Ordinary Share; and
- 45% of the Options granted will vest if the cumulative revenue of the Company reported in the audited accounts for the three financial years ended 31 December 2018 exceeds £23m.
Following the grant of Options, the total number of Options outstanding over unissued Ordinary Shares is 2,961,208 Ordinary Shares, representing approximately 14.5% of the Company's issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1. | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Names | Steven Powell - Chief Executive Officer Nick Walters - Chief Financial Officer Jennifer Barnett - Chief Scientific Officer Ricky Dolphin - Technical & Operations Director |
2. | Reason for the Notification | |
a) | Position/status | See 1(a) above for positions - all classified as PDMRs of the Company |
b) | Initial notification/ Amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Cambridge Cognition Holdings Plc |
b) | LEI | n/a |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | In each case, the grant of Options over Ordinary Shares on 3 November 2016
|
Identification code | GB00B8DV9647 | |
b) | Nature of the transaction | Grant of Options over Ordinary Shares
|
c) | Price(s) and volume(s) | Price: n/a Volumes: Steven Powell - 550,000 Options Nick Walters - 150,000 Options Jennifer Barnett - 150,000 Options Ricky Dolphin - 25,000 Options |
d) | Aggregated information: · Aggregated volume · Price | n/a |
e) | Date of the transaction | 3 November 2016 |
f) | Place of the transaction | Outside a trading venue |
Enquiries
Cambridge Cognition Holdings PLC | |
Steven Powell, Chief Executive Officer Noah Konig, Director of Product Marketing and Communications | Tel: 01223 810 700 press@camcog.com |
finnCap Ltd (NOMAD and Joint Broker) | Tel: 020 7220 0500 |
Geoff Nash / Simon Hicks | (Corporate Finance) |
Alice Lane | (Corporate Broking)
|
Hybridan LLP (Joint Broker) Claire Noyce | Tel: 020 3764 2341 (Corporate Broking) |
Notes to editors
About Cambridge Cognition
Cambridge Cognition is an international neuroscience company which develops and markets near patient cognitive assessment products to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders.
For over 30 years the company's patented technology has advanced the assessment of cognition to accelerate the development of safe and effective treatments, improve patient outcomes and measure cognitive health throughout life.
Partners include the world's leading biotechnology and pharmaceutical companies, academic institutions and public-private healthcare providers.
www.cambridgecognition.com